- Home
- EW
as 10-30-2025 9:32am EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 45.5B | IPO Year: | 2000 |
| Target Price: | $88.82 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.02 | EPS Growth: | 188.09 |
| 52 Week Low/High: | $64.89 - $84.66 | Next Earning Date: | 10-30-2025 |
| Revenue: | $5,685,100,000 | Revenue Growth: | 9.14% |
| Revenue Growth (this year): | 13.26% | Revenue Growth (next year): | 9.72% |
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chopra Daveen | EW | CVP, TMTT | Aug 25 '25 | Sell | $81.95 | 2,500 | $204,865.00 | 30,996 | |
| Wood Larry L | EW | Global President TAVR & Surg | Aug 18 '25 | Sell | $78.06 | 8,950 | $698,679.07 | 206,900.391 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
The Fly
23 days ago
Netflix upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
MT Newswires
23 days ago
Evercore ISI Upgrades Edwards Lifesciences to Outperform From In Line, Adjusts PT to $88 From $80
Barchart
24 days ago
Here's What to Expect From Edwards Lifesciences’ Next Earnings Report
Zacks
a month ago
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
MT Newswires
a month ago
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $94 From $101, Maintains Buy Rating
Simply Wall St.
a month ago
The Returns On Capital At Edwards Lifesciences (NYSE:EW) Don't Inspire Confidence
MT Newswires
a month ago
Stifel Adjusts Price Target on Edwards Lifesciences to $85 From $95, Maintains Buy Rating
Insider Monkey
a month ago
Becton, Dickinson and Company (BDX): A Healthcare Leader Among Cheap Dividend Stocks
Compare EW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.